Telehealth provider will make its big game debut as the semaglutide shortage continues to sustain the firm’s lower-priced injectables.

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their weight in 36 weeks, according to early-stage trial results on Friday, boosting the drugmaker's shares.

There’s an obesity epidemic and we feel we can bring a ton of awareness to people through the Super Bowl,” said Dan Kenger, chief design officer at Hims & Hers. “There are very few live TV events that we as America all come around and congregate for and this provides a good platform to get that message out there.

Novo Nordisk A/S soared the most since August 2023 after an experimental shot delivered as much as 22% weight loss in an early-stage trial, boosting investors’ hopes for the drugmaker’s pipeline.

Telehealth company's spot decries medications from others as "priced for profits, not patients," while its own weight-loss drugs are "affordable."